Smiths Medical - Smiths Group plc


The cookie settings on this website are set to ‘allow all cookies’. Leaving your settings to ‘allow all cookies’ means you consent to a website remembering your preferences and generally enhancing the user experience. If you prefer a website to not remember your preferences, you can change your settings at any time by changing the privacy settings of your browser.

Find out more about cookies >

Where we operate

Manufacturing is concentrated in Mexico, the US and UK, Italy, Germany and China. We sell to over 120 markets worldwide, the US being our largest single market with around 50% of sales.

View map

Smiths Medical is a leading supplier of specialist medical devices, consumables and equipment for global markets.

In medication delivery, our devices help treat cancer patients and provide relief to those in pain. Our vital care products reduce hospital-acquired infections, manage patients’ airways before, during, and after surgery, maintain body temperature and assist reproduction through IVF therapy. Our safety products keep health workers safe by helping prevent needlestick injuries and reducing cross-infections.

Key facts

Employees 7,900

2013 Headline revenue £850m

2013 Operating profit margin 22.2%

Principal operations regions

We have operations in over 30 countries with manufacturing concentrated in Mexico, US, UK, Italy, Germany and China. We sell to approximately 120 markets and, while the US continues to be our largest single market with around 50% of sales, we are investing to build our presence in selected emerging markets.

Competitive strengths

  • Strong market positions in niche areas
  • Highly recognised and respected brands
  • Reputation for high quality and safety
  • Differentiated lower risk, short residency, interventional devices
  • Innovative pipeline and new product launches
  • Extensive global sales network

Growth drivers

  • Ageing populations
  • Safety focus and legislation requirements
  • Growing incidence of chronic diseases
  • Growth of alternate site care
  • Rising healthcare spend in developing markets, offsetting budget constraints in developed markets


We estimate that three-quarters of our end customers are hospitals, with the remainder comprising the alternate care market such as homecare, clinics and other surgery centres, as well as OEM relationships. We have a direct sales presence in over 20 countries, and distribution arrangements in approximately 100 others.

Financial highlights

Revenue performance £m

Revenue by sector £850m

  1. Medication delivery 28%
  2. Vital care 42%
  3. Safety devices 30%


The competitive landscape for Smiths Medical is complex as we compete with different companies across our broad product portfolio. Our major competitors include Covidien, Teleflex, B Braun, Becton Dickinson, C R Bard, 3M (Arizant), Hospira and CareFusion. We often compete with a small portion of a major competitor’s medical business, as well as with smaller, single product line companies trying to gain entrance into a particular market. In emerging markets, we compete with both large multinational companies and smaller domestic players.


Our strategy is to actively engage suppliers in product innovation, value engineering and a commitment to quality. Our goal is to reduce product and supply chain costs, improve delivery performance and ensure supply continuity plans. The majority of our direct spending is on resins, plastic injection mouldings, and electronics.

Useful links


back to top
Celebrating 100 years on the London Stock Exchange

Smiths Group divisions:

John Crane, Smiths Medical, Smiths Detection, Smiths Interconnect, Flex-Tek

Smiths Group plc:
Registered office 2nd Floor, Cardinal Place, 80 Victoria Street, London, SW1E 5JL
Incorporated in England No. 137013
Copyright 2013 Smiths Group plc.
All rights Reserved | Legal Notice | Privacy Policy | Cookie Policy